Evidence map›Paper›PMID 41562982›Full record

ArticleMethods and protocols2025

Development of an ELISA Using Recombinant Chimeric SM Protein for Serological Detection of SARS-CoV-2 Antibodies.

Gulnur Nakhanova, Olga Chervyakova, Kamshat Shorayeva, Aisha Issabek, Sabina Moldagulova, Asankadyr Zhunushov, Aknur Ulankyzy, Aigerim Zhakypbek, Alisher Omurtay, Aziz Nakhanov and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Methods and protocols, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Gulnur NakhanovaResearch Institute for Biological Safety Problems LLP, National Holding QazBioPharm JSC, Almaty 080409, Kazakhstan.ORCID 0000-0002-5500-9913
Olga ChervyakovaResearch Institute for Biological Safety Problems LLP, National Holding QazBioPharm JSC, Almaty 080409, Kazakhstan.ORCID 0000-0002-7954-6246
Kamshat ShorayevaResearch Institute for Biological Safety Problems LLP, National Holding QazBioPharm JSC, Almaty 080409, Kazakhstan.
Aisha IssabekResearch Institute for Biological Safety Problems LLP, National Holding QazBioPharm JSC, Almaty 080409, Kazakhstan.ORCID 0000-0002-5623-7571
Sabina MoldagulovaResearch Institute for Biological Safety Problems LLP, National Holding QazBioPharm JSC, Almaty 080409, Kazakhstan.ORCID 0000-0002-8353-1629
Asankadyr ZhunushovInstitute of Biotechnology, National Academy of Sciences of the Kyrgyz Republic, Bishkek 720071, Kyrgyzstan.
Aknur UlankyzyResearch Institute for Biological Safety Problems LLP, National Holding QazBioPharm JSC, Almaty 080409, Kazakhstan.
Aigerim ZhakypbekResearch Institute for Biological Safety Problems LLP, National Holding QazBioPharm JSC, Almaty 080409, Kazakhstan.
Alisher OmurtayResearch Institute for Biological Safety Problems LLP, National Holding QazBioPharm JSC, Almaty 080409, Kazakhstan.
Aziz NakhanovResearch Institute for Biological Safety Problems LLP, National Holding QazBioPharm JSC, Almaty 080409, Kazakhstan.ORCID 0000-0002-6593-0271
Zharkinay AbsatovaResearch Institute for Biological Safety Problems LLP, National Holding QazBioPharm JSC, Almaty 080409, Kazakhstan.
Yeraly ShayakhmetovResearch Institute for Biological Safety Problems LLP, National Holding QazBioPharm JSC, Almaty 080409, Kazakhstan.
Kuanysh JekebekovResearch Institute for Biological Safety Problems LLP, National Holding QazBioPharm JSC, Almaty 080409, Kazakhstan.
Temirlan BaiseitResearch Institute for Biological Safety Problems LLP, National Holding QazBioPharm JSC, Almaty 080409, Kazakhstan.
Aslan KerimbayevResearch Institute for Biological Safety Problems LLP, National Holding QazBioPharm JSC, Almaty 080409, Kazakhstan.

Funding

Science Committee of the Ministry of Education and Science BR24992948
6 · The paper itself

Abstract

The emergence and spread of coronavirus infections have created a necessity to develop serological methods for assessing population immunity. The enzyme-linked immunosorbent assay (ELISA) remains one of the most accessible and informative approaches for these purposes. The choice of recombinant proteins plays an important role in the sensitivity and specificity of the test system, and in this regard, the creation of a domestic ELISA based on the chimeric SM protein to the SARS-CoV-2 virus is relevant. In this work, a recombinant chimeric SM protein expressed in the

Indexed as

cloningenzyme-linked immunosorbent assayexpressionpurificationrecombinant chimeric protein

Identifiers

PMID41562982
PMCPMC12821618

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.